Logo Image

Husseini K. Manji, MD

Articles by Husseini K. Manji, MD

Boosting Brain Health After COVID-19: A Convergence Solution

ByHarris A. Eyre, MD, PhD,Jessica Carson,Erin Smith,Helen Lavretsky, MD, MS,Charles F. Reynolds III, MD,Husseini K. Manji, MD,Walter D. Dawson, DPhil,Laura Booi, PhD,Mark Heinemeyer,Jeffrey L. Cummings, MD, ScD,Ernestine Fu, PhD,Eric A. Storch, PhD,William Hynes, DPhil,Eric J. Lenze, MD,Retsina Meyer, PhD,Ian Macrae, PhD,Antonella Santuccione Chadha, MD,Ryan Abbott, MD, JD, PhD,Sandra Bond Chapman, PhD,Ian Robertson, PhD,Carol Graham,Brisa S. Fernandes, MD, MSc, PhD,David G. Angeler, PhD,Adrienne Grzenda, MD, PhD,Agustin Ibañez, PhD,Zoltan Sarnyai, MD, PhD,Sofia Marcha,Michael Berk, MD, PhD,Patrick Brannelly

How can we face the current pandemic while addressing the brain health crisis?

Focus on Bipolar Disorder

ByCarlos A. Zarate, Jr, MD,Husseini K. Manji, MD

Although several antimanic agents are available to treat individuals with bipolar disorder (BD), many patients have a less than satisfactory response or experience adverse effects.1 With the exception of lithium, all of the current antimanic agents are either anticonvulsant or antipsychotic drugs. It is remarkable that no drug has been developed specifically for BD, especially because this illness was conceptualized more than a century ago.

Latest Updated Articles